Tumor-Infiltrating CD8+T Cells Driven by the Immune Checkpoint-Associated Gene IDO1 Are Associated With Cervical Cancer Prognosis

被引:7
作者
Zhang, Shun [1 ]
Wan, Junhui [2 ]
Chen, Minjie [3 ]
Cai, Desheng [2 ]
Xu, Junlan [2 ]
Chen, Qi [4 ]
机构
[1] Nanchang Univ, Affiliated Hosp 1, Gen Surg Dept, Nanchang, Jiangxi, Peoples R China
[2] Nanchang Univ, Affiliated Hosp 1, Obstet & Gynaecol Dept, Nanchang, Jiangxi, Peoples R China
[3] Nanchang Univ, Queen Mary Coll, Nanchang, Jiangxi, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Obstet & Gynecol Dept, Nanchang, Jiangxi, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
cervical cancer; differentially expressed genes; immune infiltration; tumor immunity; tumor-infiltrating CD8(+) T cells; LYMPHOCYTE GRADE; MICROENVIRONMENT; EXPRESSION; MECHANISM; BLOCKADE; SURVIVAL; SUBSETS; CTLA-4;
D O I
10.3389/fonc.2021.720447
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor-infiltrating immune cells, associated with tumor progression, are promising prognostic biomarkers. However, the relationship between levels of gene expression and that of immune cell infiltration in cervical cancer prognosis is unknown. In this study, three cervical cancer gene expression microarrays (GSE6791, GSE63678 and GSE55940) were obtained from the GEO database. The IDO1 gene was identified by differentially expressed gene screening. The gene expression profiles of TCGA and GTEx databases along with comprehensive bioinformatics analysis identified that the IDO1 gene was upregulated in cervical cancer with significant difference in expression at different N stages. In addition, it was also upregulated in HPV16 positive sample. The pan-cancer analysis identified that IDO1 was highly expressed in most cancers. TIMER analysis revealed that the expression of IDO1 in CESC shows positive correlation with CD8(+) T cells, CD4(+) T cells, neutrophils, dendritic cells. IDO1 expression showed remarkable positive correlation with all immune cell markers except M1 macrophages. CD8(+) T cell infiltration GSEA results showed that IDO1 was mainly associated with tumor immune-related signaling pathways.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The evolving understanding of immunoediting and the clinical impact of immune escape
    McCoach, Caroline E.
    Bivona, Trever G.
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1248 - 1252
  • [22] Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
    Mitchell, Tara C.
    Hamid, Omid
    Smith, David C.
    Bauer, Todd M.
    Wasser, Jeffrey S.
    Olszanski, Anthony J.
    Luke, Jason J.
    Balmanoukian, Ani S.
    Schmidt, Emmett V.
    Zhao, Yufan
    Gong, Xiaohua
    Maleski, Janet
    Leopold, Lance
    Gajewski, Thomas F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3223 - +
  • [23] High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy
    Mitra, Devarati
    Horick, Nora K.
    Brackett, Diane G.
    Mouw, Kent W.
    Hornick, Jason L.
    Ferrone, Soldano
    Hong, Theodore S.
    Mamon, Harvey
    Clark, Jeffrey W.
    Parikh, Aparna R.
    Allen, Jill N.
    Ryan, David P.
    Ting, David T.
    Deshpande, Vikram
    Wo, Jennifer Y.
    [J]. ONCOLOGIST, 2019, 24 (06) : E275 - E283
  • [24] IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
    Munn, David H.
    Mellor, Andrew L.
    [J]. TRENDS IN IMMUNOLOGY, 2016, 37 (03) : 193 - 207
  • [25] Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
    Nayak-Kapoor, Asha
    Hao, Zhonglin
    Sadek, Ramses
    Dobbins, Robin
    Marshall, Lisa
    Vahanian, Nicholas N.
    Ramsey, W. Jay
    Kennedy, Eugene
    Mautino, Mario R.
    Link, Charles J.
    Lin, Ray S.
    Royer-Joo, Stephanie
    Liang, Xiaorong
    Salphati, Laurent
    Morrissey, Kari M.
    Mahrus, Sami
    McCall, Bruce
    Pirzkall, Andrea
    Munn, David H.
    Janik, John E.
    Khleif, Samir N.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [26] Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
  • [27] HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
    Nijland, Marcel
    Veenstra, Rianne N.
    Visser, Lydia
    Xu, Chuanhui
    Kushekhar, Kushi
    van Imhoff, Gustaaf W.
    Kluin, Philip M.
    van den Berg, Anke
    Diepstra, Arjan
    [J]. ONCOIMMUNOLOGY, 2017, 6 (04):
  • [28] CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
    Ott, Patrick A.
    Hodi, F. Stephen
    Robert, Caroline
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5300 - 5309
  • [29] Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells
    Pappa, Kalliopi I.
    Polyzos, Alexander
    Jacob-Hirsch, Jasmine
    Amariglio, Ninette
    Vlachos, George D.
    Loutradis, Dimitrios
    Anagnou, Nicholas P.
    [J]. PLOS ONE, 2015, 10 (11):
  • [30] Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components
    Pardee, Keith
    Green, Alexander A.
    Takahashi, Melissa K.
    Braff, Dana
    Lambert, Guillaume
    Lee, Jeong Wook
    Ferrante, Tom
    Ma, Duo
    Donghia, Nina
    Fan, Melina
    Daringer, Nichole M.
    Bosch, Irene
    Dudley, Dawn M.
    O'Connor, David H.
    Gehrke, Lee
    Collins, James J.
    [J]. CELL, 2016, 165 (05) : 1255 - 1266